| A new delivery system for contraceptive steroids. | |
| | |
MedLine Citation:
|
PMID: 3118719 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Long-acting forms of contraception that take advantage of the tissue compatibility of silicone rubber, a polymer of dimethylsiloxane, have been developed. The most advanced type of subdermal contraceptive capsule contains about 36 to 40 mg of levonorgestrel and is 30 mm in length and 2.4 mm in diameter (Norplant). The set of six implants is placed under the skin of the upper arm with a 10-gauge trocar with the use of a local anesthetic. The basis for the antifertility effect of these implants is continuous, low-dose progestogen therapy without the use of estrogen. The capsules release a total of approximately 39 micrograms of levonorgestrel each day. The blood progestogen level achieved through this microabsorption delivery system is 0.25 to 0.3 ng/ml. There is a sufficient supply of steroid in the capsules to maintain this blood progestogen level for 5 to 6 years. Since the capsules can be removed at any time, this contraceptive method is voluntarily reversible. The effectiveness of these subdermal implants has been evaluated in long-term studies that have progressed for well over 5 years. Therefore one clinic visit eliminates nearly 2000 days of concern over having to remember to take a pill on schedule. There has been sufficient experience to assure that fertility recurs promptly after removal of the subdermal implants. Long-acting forms of contraception that take advantage of the tissue compatibility of silicone rubber, a polymer of dimethylsiloxane, have been developed. The most advanced type of subdermal contraceptive capsule contains about 36-40 mg of levonorgestrel and is 30 mm in length and 2.4 mm in diameter (Norplant). The set of 6 implants is placed under the skin of the upper arm with a 10-gauge trocar with the use of a local anesthetic. The basis for the antifertility effect of these implants is continuous, low-dose progestogen therapy without the use of estrogen. The capsules release a total of approximately 39 mcg of levonorgestrel each day. The blood progestogen level achieved through this microabsorption delivery system is 0.25-0.3 ng/ml. There is a sufficient supply of steroid in the capsules to maintain this blood progestogen level for 5-6 years. Since the capsules can be removed at any time, this contraceptive method is voluntarily reversible. The effectiveness of these subdermal implants has been evaluated in longterm studies that have progressed for well over 5 years. Therefore 1 clinic visit eliminates nearly 2000 days of concern over having to remember to take a pill on schedule. There has been sufficient experience to assure that fertility recurs promptly after removal of the subdermal implants. |
| | |
Authors:
|
S Segal |
Related Documents
:
|
18498839 - Extra-aortic implantable counterpulsation pump in chronic heart failure. 19578449 - Complete caval thrombosis secondary to an implanted venous port--a case study. 3828159 - A rabbit model for implanting continuous drug infusion pumps. 21789489 - Clostridium beijerinckii mutant with high inhibitor tolerance obtained by low-energy io... 8555619 - Modified fabrication techniques lead to improved centrifugal blood pump performance. 17050399 - Satisfaction of individuals treated long-term with continuous infusion of intrathecal b... 349139 - The kinetics of anterior tooth display. 12518699 - Diagnoses, clinical classification, and proposed treatment of spontaneous early exposur... 8558399 - 10-year periodontal response to resin bonded bridges. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: American journal of obstetrics and gynecology Volume: 157 ISSN: 0002-9378 ISO Abbreviation: Am. J. Obstet. Gynecol. Publication Date: 1987 Oct |
Date Detail:
|
Created Date: 1987-11-25 Completed Date: 1987-11-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370476 Medline TA: Am J Obstet Gynecol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1090-2 Citation Subset: AIM; IM; J |
Affiliation:
|
Population Sciences, Rockefeller Foundation, New York, New York. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Contraceptive Agents, Female / administration & dosage*, adverse effects Drug Implants Female Humans Levonorgestrel Norgestrel / administration & dosage*, adverse effects, blood Pregnancy |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptive Agents, Female; 0/Drug Implants; 6533-00-2/Norgestrel; 797-63-7/Levonorgestrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phasic approach to oral contraceptives.
Next Document: Comparison of chondroitin sulfate to McCarey-Kaufman medium for corneal storage.